Lately, there has been an exponential advance in the biomedical field. Nonetheless these discoveries do not really mean direct mean direct benefits for the patients, or take a long time to arrive to the population. The ...

The majority of non-small-cell lung cancer (NSCLC) patients present with locally advanced (35%) or metastatic disease (40%); in this setting, it is of the utmost importance to balance efficacy with toxicity. However, with ...

[ES] Introducción En el cáncer de pulmón no microcítico (CPNM) es necesaria la identificación de biomarcadores que permitan la caracterización molecular del tumor y, con ello, adecuar el manejo de los pacientes1. En este ...

[EN] Lung cancer is the leading cause of cancer death worldwide. Therefore, advances in the diagnosis and treatment of the disease are urgently needed. miRNAs are a family of small, noncoding RNAs that regulate gene ...

[EN] In addition to malignant neoplastic cells, cancer tissues also include immune cells, fibroblasts, and endothelial cells, including an abundant collection of growth factors, proangiogenic mediators, cytokines, chemokines, ...